Division of Johnson & Johnson
Latest From Ethicon Inc.
The global market for endoscopic and pelvic surgery procedures is expected to reach $17.7bn in 2023, a CAGR of 6.4%, driven by patients' demand for less invasive surgeries and physicians' preference for minimally invasive surgeries versus open surgeries. By 2023, the number of general and pelvic endoscopic procedures performed globally will reach about 29.7 million, representing a CAGR of 3.6%.
Ethicon will acquire the assets and licenses of TachoSil for $400m and add about 80 Takeda employees, while Takeda will maintain ownership of the TachoSil manufacturing facility in Linz, Austria.
As widely anticipated, Takeda has reached an agreement to divest an ex-Shire ophthalmology drug, as it streamlines the combined post-acquisition business to focus on core therapeutic pillars.
Product liability cases alleging manufacturers of pelvic mesh are responsible for patient injuries continued even as the US FDA is halting sales of the product. In the most recent verdict, a Philadelphia jury said Johnson & Johnson was not responsible for adverse events experienced by a Pennsylvania woman.
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Therapeutic Areas
- Wound Healing & Tissue Repair
- North America
- Parent & Subsidiaries
Johnson & Johnson
- Acclarent Inc.
- Advanced Sterilization Products
- CardioVations Inc.
- Guangzhou Bioseal Biotechnology Co. Ltd.
- Gynecare Inc.
- Heartport Inc.
- Johnson & Johnson Medical Inc.
- Medtrex Inc.
- Mentor Corp.
- Omrix Biopharmaceuticals Inc.
- Torax Medical Inc.
- Vascular Control Systems Inc.
- Ethicon Inc.
- Senior Management
- Contact Info
Phone: (908) 218-0707
Rte. 22 West
Somerville, NJ 08876
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.